Literature DB >> 19033017

Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study.

Lilian Grigorian-Shamagian1, Fernando Otero Raviña, Emad Abu Assi, Rafael Vidal Perez, Elvis Teijeira-Fernandez, Alfonso Varela Roman, Laura Moreira Sayagues, Jose Ramon Gonzalez-Juanatey.   

Abstract

BACKGROUND: The aim of the study was to examine the causes of the death of patients with heart failure (HF) and evaluate the differences in this respect between patients with and without depression of left ventricular ejection fraction (LVEF).
METHOD: All patients hospitalized with HF between 1995 and 2002 in the cardiology service of a tertiary hospital were assessed. LVEF was evaluated by echocardiography during hospitalization and was considered normal when it was > or =50%. After a mean follow-up time of 3.7 +/- 2.8 years, 615 cases had terminated in death.
RESULTS: The most common cause was refractory HF, both in the whole group (39%) and in both the subgroups defined with respect to LVEF (normal and depressed). There was no statistically significant difference between the normal and depressed subgroups as regard the distribution of deaths, although the depressed group showed a somewhat greater incidence of sudden death (21% as against 16% in the normal group) and a somewhat smaller incidence of death due to refractory HF (37% as against 47%). However, in the depressed LVEF group, the cumulative risk of death due to acute myocardial infarction in the first 1.5 years first increased rapidly and then more slowly, whereas the reverse pattern was held in the normal left ventricular systolic function group, in which it was the cumulative risks of death from noncardiovascular or vascular noncardiac causes that initially increased more rapidly than later.
CONCLUSIONS: The spectrum of causes of death among patients with HF who have been hospitalized is independent of LVEF in the long term. In the short term, there are differences between patients with normal LVEF and depressed LVEF as regard the dynamics of the risks of death from acute myocardial infarction, noncardiac vascular causes, and noncardiovascular causes. These results may help orient the short-term and long-term management of HF, especially for patients with normal LVEF, for whom there is still no well-established consensus strategy.

Entities:  

Mesh:

Year:  2008        PMID: 19033017     DOI: 10.1016/j.ahj.2008.07.011

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Congestion is the driving force behind heart failure.

Authors:  Maya Guglin
Journal:  Curr Heart Fail Rep       Date:  2012-09

2.  A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction.

Authors:  Douglas S Lee; Philimon Gona; Irene Albano; Martin G Larson; Emelia J Benjamin; Daniel Levy; William B Kannel; Ramachandran S Vasan
Journal:  Circ Heart Fail       Date:  2010-11-11       Impact factor: 8.790

Review 3.  Use of stem cells in heart failure treatment: where we stand and where we are going.

Authors:  Luis A Sánchez; Carlos Enrique Guerrero-Beltrán; Andrea M Cordero-Reyes; Gerardo García-Rivas; Guillermo Torre-Amione
Journal:  Methodist Debakey Cardiovasc J       Date:  2013 Oct-Dec

Review 4.  Epidemiology and clinical course of heart failure with preserved ejection fraction.

Authors:  Carolyn S P Lam; Erwan Donal; Elisabeth Kraigher-Krainer; Ramachandran S Vasan
Journal:  Eur J Heart Fail       Date:  2010-08-03       Impact factor: 15.534

Review 5.  Safety and efficacy of new anticoagulants in patients with heart failure.

Authors:  Ron Pisters; Gregory Y H Lip
Journal:  Curr Heart Fail Rep       Date:  2013-03

6.  Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.

Authors:  Carolyn S P Lam; Peter E Carson; Inder S Anand; Thomas S Rector; Michael Kuskowski; Michel Komajda; Robert S McKelvie; John J McMurray; Michael R Zile; Barry M Massie; Dalane W Kitzman
Journal:  Circ Heart Fail       Date:  2012-08-10       Impact factor: 8.790

7.  Diuretics as pathogenetic treatment for heart failure.

Authors:  Maya Guglin
Journal:  Int J Gen Med       Date:  2011-01-23

Review 8.  Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction.

Authors:  Rohan Samson; Abhishek Jaiswal; Pierre V Ennezat; Mark Cassidy; Thierry H Le Jemtel
Journal:  J Am Heart Assoc       Date:  2016-01-25       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.